CSF t-tau levels can serve as a neuronal injury marker and are increased in many neurodegenerative diseases, such as Creutzfeldt-Jakob disease [35], AD, DLB, and frontotemporal dementia (FTD), whereas CSF p-tau 181 or p-tau 231 (tau phosphorylated at threonine 181 or threonine 231) levels increase more specifically in AD than in other neurodegenerative diseases. Here, MAPT is linked to frontotemporal dementia.